Related Experiment Video
Updated: Mar 15, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Association between apolipoprotein B EcoRI polymorphisms and coronary heart disease : A meta-analysis
Yeda Chen1, Jingtang Zeng1, Yiqing Tan1
1Institute of Medical Systems Biology, and School of Public Health, Guangdong Medical University, No. 1 New City Avenue, Songshan Lake Science and Technology Industry Park, 523808, Dongguan, Guangdong, China.
Objective:
The study was carried out to examine the association between apolipoprotein B (ApoB) EcoRI polymorphism (E- vs. E+) (rs1042031) and coronary heart disease (CHD) risk by systematically analyzing multiple independent studies.
Methods:
The Hardy-Weinberg equilibrium (HWE) test was applied to assess genotype frequency distribution in healthy controls. The quality of the studies was assessed using the Newcastle-Ottawa scale (NOS). Power analysis was performed with Power and Precision V4 software. A fixed effect model was used because no deviation from homogeneity was found. Publication bias was quantified and examined with Begg's funnel plot test and Egger's linear regression method. The meta-analysis was performed by Stata 12.0 software.
Results:
A total of 21 eligible association studies were merged in this meta-analysis and the pooled sample consisted of 2994 CHD patients and 3258 healthy controls. No significant publication bias and heterogeneity were observed in these studies. The pooled odds ratio (OR) and 95% confidence interval (CI) of E- vs. E+ were 1.18 (1.06-1.32). The pooled OR (95% CI) of E+ E- + E- E- vs. E+ E+ was 1.18 (1.04-1.34).
Conclusions:
This meta-analysis indicated that ApoB EcoRI confers a moderate risk for CHD and the E- allele at this locus might be a susceptibility allele for the development of CHD.
More Related Videos
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease I: Introduction
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

